Business
Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kgThe substantial reduction in T cell activity highlights the potential efficacy of IMP761 in treating autoimmune diseasesSingle ascending dose levels will continue with 2.5, 7 and 14 mg/kgAdditional data from the Phase I to follow in second half of CY2025 SYDNEY, AUSTRALIA, June 23, 2025 (GLOBE NEWSWIRE) -- Immutep Limite
About this update from Immutep Ltd
[{"type":"image","alt":"Immutep Limited","displaySize":"","headline":null,"caption":"Immutep Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":246,"height":103,"url":"https://media.zenfs.com/en/globenewswire.com/60325dae98d9e851c4236017024da578"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PIIfOSI4irhaeByOTtn6bg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/60325dae98d9e851c4236017024da578","width":246,"height":103}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kg","length":178,"tagName":"p"}]},{"val":[{"type":"text","content":"The substantial reduction in T cell activity highlights the potential efficacy of IMP761 in treating autoimmune diseases","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"Single ascending dose levels will continue with 2.5, 7 and 14 mg/kg","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"Additional data from the Phase I to follow in second half of CY2025","length":67,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":432,"olType":false},{"type":"text","content":" SYDNEY, AUSTRALIA, June 23, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces positive initial efficacy data and continued favourable safety data from the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases.","length":445,"tagName":"p"},{"type":"text","content":"Through the highest dosing level to date (0.9 mg/kg of IMP761), there have been no treatment-related adverse events in healthy participants. Additionally, pharmacodynamic data at this dosing level show that the inhibition of T cell infiltration in the skin at day 10 following a neoantigen rechallenge has already reached 80%. Given the encouraging efficacy and safety, Immutep is continuing with single ascending dose levels of 2.5, 7 and 14 mg/kg.","length":449,"tagName":"p"},{"type":"text","content":"The LAG-3 (lymphocyte-activation gene-3) immune check...